Is it safe for an adult with elevated blood pressure to take nattokinase, and what dosage and monitoring are recommended?

Nattokinase and Blood Pressure

Nattokinase can be considered as an adjunctive supplement for adults with elevated blood pressure, but it should NOT replace evidence-based antihypertensive medications that have proven mortality and morbidity benefits. The 2025 AHA/ACC guidelines make no mention of nattokinase and instead provide clear Class 1 recommendations for pharmacologic therapy with proven agents (ACE inhibitors, ARBs, thiazides, calcium channel blockers) when blood pressure thresholds are met 1, 2.

Evidence-Based Treatment Thresholds

The current guidelines establish firm medication initiation criteria 1:

• SBP ≥140 mmHg or DBP ≥90 mmHg: Start proven antihypertensive medications (Class 1, Level A)
• SBP ≥130 mmHg or DBP ≥80 mmHg: Start medications if patient has clinical CVD, diabetes, CKD, or 10-year CVD risk ≥7.5% (Class 1, Level A)
• Lower risk patients: Consider medications after 3-6 months of lifestyle intervention if BP remains ≥130/80 mmHg (Class 1, Level B-R)

Nattokinase: What the Research Shows

Blood Pressure Effects

The most recent meta-analysis found modest BP reductions with nattokinase supplementation 3:

• Systolic BP reduction: -3.45 mmHg (95% CI: -4.37 to -2.18)
• Diastolic BP reduction: -2.32 mmHg (95% CI: -2.72 to -1.92)

An earlier North American trial showed similar results, with more pronounced effects in males (diastolic BP dropped from 86 to 81 mmHg, p<0.006) 4. A 2008 Asian study reported net reductions of -5.55 mmHg systolic and -2.84 mmHg diastolic 5.

Critical limitation: A 3-year randomized controlled trial found nattokinase had no effect on subclinical atherosclerosis progression, blood pressure, or cardiovascular biomarkers in 265 individuals at low CVD risk 6. This contradicts the shorter-term studies and raises questions about long-term cardiovascular benefit.

Safety Profile

Toxicology studies demonstrate good safety 7:

• No mutagenic or clastogenic effects
• NOAEL (no observed adverse effect level) of 1000 mg/kg/day in rats
• Well-tolerated in human trials with no significant adverse events reported

Clinical Recommendation Algorithm

If BP is ≥140/90 mmHg or ≥130/80 mmHg with CVD/diabetes/CKD:

1. Initiate proven antihypertensive medication immediately per guidelines 1, 2
2. Implement lifestyle modifications (DASH diet, sodium <2,300 mg/day ideally <1,500 mg/day, potassium 3,500-5,000 mg/day, exercise ≥150 min/week) 2
3. Nattokinase may be added as adjunctive therapy but should never delay or replace guideline-directed medical therapy

If BP is 130-139/80-89 mmHg without high-risk features:

1. Start with 3-6 months of intensive lifestyle modification 1
2. Nattokinase could be considered during this period as part of a comprehensive approach
3. If BP remains elevated after 3-6 months, initiate proven pharmacologic therapy

If BP is <130/80 mmHg (elevated but not hypertensive):

1. Focus on lifestyle interventions 2
2. Nattokinase may be considered for modest additional BP reduction
3. Monitor BP regularly

Dosing and Monitoring

Typical nattokinase dosing in trials: 2,000-4,000 fibrinolytic units (FU) daily, equivalent to approximately 100-200 mg/day 3, 4, 5

Monitoring recommendations:

• Baseline BP measurement (proper technique: seated, rested 5 minutes, appropriate cuff size)
• Recheck BP every 2-4 weeks initially
• If taking anticoagulants or antiplatelet agents, monitor for bleeding risk (nattokinase has fibrinolytic properties)
• Avoid in patients on warfarin, DOACs, or with bleeding disorders
• Check potassium if taking ACE inhibitors, ARBs, or potassium-sparing diuretics (though nattokinase itself doesn't affect potassium) 2

Critical Caveats

The 3-5 mmHg BP reduction from nattokinase is modest compared to proven antihypertensive medications (which typically reduce SBP by 10-15 mmHg). More importantly, unlike ACE inhibitors, ARBs, thiazides, and calcium channel blockers, nattokinase has no proven mortality or cardiovascular event reduction 6.

Dose-dependent effects remain unclear: The 2023 meta-analysis suggests low-dose nattokinase may adversely affect lipid profiles (increased total cholesterol and LDL) 3, though this requires confirmation.

Bleeding risk: Given its fibrinolytic mechanism, avoid combining with anticoagulants or in patients with bleeding disorders 8, 9.

Population variability: Recent data suggest nattokinase efficacy may vary by blood group and age, with AB− individuals showing longest clot dissolution times 8, though clinical significance is uncertain.